Next 10 |
2024-10-04 16:27:24 ET More on Plus Therapeutics Seeking Alpha’s Quant Rating on Plus Therapeutics Historical earnings data for Plus Therapeutics Financial information for Plus Therapeutics Read the full article on Seeking Alpha For further det...
Rhenium ( 186 Re) Obisbemeda delivered by convection enhanced delivery (CED) continues to show safety, response, and potential efficacy Mean Phase 2 absorbed dose was 300 Gy and 89% of patients exceeded the minimal dose threshold of 100 Gy ReSPECT-GBM Phase 1/2 trial...
A look at the top 10 most actives in the United States Kaixin Holdings (KXIN) rose 185.6% to $0.257 on volume of 221,326,351 shares NIO Inc. American depositary shares each representing one Class A (NIO) rose 13.8% to $7.4226 on volume of 58,343,558 shares NVIDIA Corporation (NVDA) fell 0.4...
2024-09-27 20:45:00 ET Recently, I hit a portfolio milestone: $3,800 in annual dividend and interest income. I hit this passive income level when I did my research for an article about my plan to hit $5,000 a year in passive income in 2025. As part of my research, I looked up my project...
AUSTIN, Texas, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system can...
AUSTIN, Texas, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CN...
2024-08-14 21:55:28 ET Plus Therapeutics, Inc. (PSTV) Q2 2024 Earnings Conference Call August 14, 2024 5:00 PM ET Company Participants Marc Hedrick – President and Chief Executive Officer Andrew Sims – Chief Financial Officer Conference Call Parti...
2024-08-14 16:50:28 ET More on Plus Therapeutics Seeking Alpha’s Quant Rating on Plus Therapeutics Historical earnings data for Plus Therapeutics Financial information for Plus Therapeutics Read the full article on Seeking Alpha For further det...
Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium ( 186 Re) Obisbemeda for Leptomeningeal Metastases Presented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE trial Management to host conference call August 14, 2024 at 5:00 p.m. ET...
2024-08-14 10:00:00 ET Major earnings expected after the bell on Wednesday include: Cisco Systems ( CSCO ) StoneCo Ltd. ( STNE ) Zomedica Corp. ( ZOM ) Lumentum Holdings ( LITE ) Canoo ( GOEV ) Read the full article on Seeking Alpha Fo...
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NASDAQ Market:
PLUS THERAPEUTICS Inc. Website:
Rhenium ( 186 Re) Obisbemeda delivered by convection enhanced delivery (CED) continues to show safety, response, and potential efficacy Mean Phase 2 absorbed dose was 300 Gy and 89% of patients exceeded the minimal dose threshold of 100 Gy ReSPECT-GBM Phase 1/2 trial...
A look at the top 10 most actives in the United States Kaixin Holdings (KXIN) rose 185.6% to $0.257 on volume of 221,326,351 shares NIO Inc. American depositary shares each representing one Class A (NIO) rose 13.8% to $7.4226 on volume of 58,343,558 shares NVIDIA Corporation (NVDA) fell 0.4...
2024-09-27 20:45:00 ET Recently, I hit a portfolio milestone: $3,800 in annual dividend and interest income. I hit this passive income level when I did my research for an article about my plan to hit $5,000 a year in passive income in 2025. As part of my research, I looked up my project...